Commentary · 5 Jan 2023
Conference abstractPublished 16 Oct 2018
Mechanism of action and clinical efficacy of mTOR blockade in lupus
University of Rochester, Roswell Park Memorial Institute, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting 1.5 million Americans with ~10% mortality over 5 years. Our recent studies unveiled a significant involvement of the mechanistic target of rapamycin (mTOR) in abnormal T-cell activation and lineage specification and autoantibody production in SLE. In accordance with a critical role for mTOR in pathogenesis, rapamycin reduced disease activity in a recently completed clinical trial. Metabolome triggers of mTOR activation and clinical responsiveness in SLE: systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% over 5 years. Although prevalence estimates vary, 1.5 million people are thought to have SLE in the United States. There is unmet medical need, as current treatments are only partially effective and have significant side effects. Our central hypothesis has been formulated on the basis of growing evidence for significant involvement of mTOR activation in abnormal T-cell activation and lineage specification and its impact on B-cell activation and production of antinuclear autoantibodies (ANA). The rationale for this study is supported by existing data in the literature providing evidence that 1) mTOR activity is increased in T cells of patients and mice with SLE; 2) mTOR controls T cells lineage specification during development and its skewing in SLE; 3) administration of rapamycin improves the clinical outcome of lupus in mice and patients; 4) rapamycin enhances renal allograft survival in patients with antiphospholipid antibodies, which represent a diagnostic criterion and a source of co-morbidity is SLE; and 5) mTOR blockade with rapamycin is known to be safe and increase overall lifespan, at least in mice. Therefore, we initiated a prospective study of rapamycin for the treatment of SLE (ClinicalTrials.gov Identifier: NCT00779194). In accordance with a critical role for mTOR in lupus pathogenesis, the blockade of mTOR reduced disease activity in 126±18 days as evidenced by well-tolerated rapamycin plasma levels of 8.7±1.2 ng/ml, which was within the targeted therapeutic range of 6-15 ng/ml. SLEDAI disease activity scores were reduced to 5.7±1.0 from 11.8±1.1 at baseline (p=0.0028). Among the patients who completed the 1 year intervention thus far, an SLE responder index of 64.3% was achieved. Rapamycin inhibited the pro-inflammatory expansion and IL-4 production of CD4-CD8- double-negative (DN) T cells, which have been found to stimulate anti-DNA production by B cells. Given that the blockade of mTORC1 abrogates disease activity in mice and patients with SLE, it is important to further establish the efficacy of rapamycin in a randomized double-blind placebo-controlled clinical trial.
Subjects
RheumatologyOrthopaedicsAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 2015
Impaired Aerobic Capacity in Systemic Lupus Erythematosus Patients: What are the Physiological Mechanisms
Conference abstract · 7 Jun 2017
CZ415, a highly selective mTOR inhibitor showing in vivo efficacy in a collagen induced arthritis (CIA) model
Conference abstract · 22 Mar 2017
Assessment of cluster differentiation 40 single nucleotide polymorphism (rs4810485) among systemic lupus erythematosus patients and correlation with clinical picture of the disease
Article · 13 Aug 2025
Herbal alternatives in the management of tooth decay: A comprehensive review of phytotherapeutic agents, mechanisms of action, clinical efficacy, and potential for integrative dental care
More from this journal
The newest in Rheumatology: Current Research.
Opinion · 19 Dec 2025
The Future of Rheumatology: Growth and Innovation
Opinion · 19 Dec 2025
Specialized Care for Complex Rheumatic Disorders
Perspective · 19 Dec 2025
Rheumatology and Musculoskeletal Health
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalRheumatology: Current Research
- SubjectRheumatology
- SubjectOrthopaedics
- BylineArticles whose byline prints “Andras Perl”

